The short-chain fatty acid butyrate prevents gut-brain amyloid-β pathology and neuroinflammation in an Alzheimer mouse model - PubMed
5 days ago
- #Butyrate
- #Alzheimer's Disease
- #Gut-Brain Axis
- Butyrate, a short-chain fatty acid, prevents amyloid-β (Aβ) pathology and neuroinflammation in an Alzheimer's mouse model.
- Alzheimer's disease (AD) patients show early gastrointestinal (GI) symptoms like constipation, linked to Aβ accumulation in the gut.
- Aβ accumulation in the gut affects the enteric nervous system (ENS) connectivity and gut function, with potential transmission to the brain.
- SAMP8 mice exhibit gut amyloid pathology and ENS alterations before memory decline, mirroring early AD progression.
- Butyrate reduces Aβ secretion, preserves ENS connectivity, and blocks Aβ accumulation in the gut, brain, and plasma in SAMP8 mice.
- Butyrate also ameliorates neuroinflammation, prevents gut dysfunction, and improves memory deficits in the AD model.
- The study suggests that targeting gut Aβ pathology early with butyrate could slow or reverse AD progression.